AIM: To analyze differences in patients' clinical course, we compared two regimes of either preemptive therapy or prophylaxis after liver transplantation. METHODS: This retrospective study was reviewed and approved by the institutional review board of the University of Leipzig. Cytomegalovirus (CMV) prophylaxis with valganciclovir hydrochloride for liver transplant recipients was replaced by a preemptive strategy in October 2009. We retrospectively compared liver transplant recipients 2 years before and after October 2009. During the first period, all patients received valganciclovir daily. During the second period all patients included in the analysis were treated following a preemptive strategy. Outcomes included one year survival and therapeutic intervention due to CMV viremia or infection. RESULTS: Between 2007 and 2010 n = 226 patients underwent liver transplantation in our center. n = 55 patients were D(+)/R(-) high risk recipients and were excluded from further analysis. A further 43 patients had to be excluded since CMV prophylaxis/preemptive strategy was not followed although there was no clinical reason for the deviation. Of the remaining 128 patients whose data were analyzed, 60 received prophylaxis and 68 were treated following a preemptive strategy. The difference in overall mortality was not significant, nor was it significant for one-year mortality where it was 10% (95%CI: 8%-28%, P = 0.31) higher for the preemptive group. No significant differences in blood count abnormalities or the incidence of sepsis and infections were observed other than CMV. In total, 19 patients (14.7%) received ganciclovir due to CMV viremia and/or infections. Patients who were treated according to the preemptive algorithm had a significantly higher rate risk of therapeutic intervention with ganciclovir [n = 16 (23.5%) vs n = 3 (4.9%), P = 0.003)]. CONCLUSION: These data suggest that CMV prophylaxis is superior to a preemptive strategy in patients undergoing liver transplantation.
AIM: To analyze differences in patients' clinical course, we compared two regimes of either preemptive therapy or prophylaxis after liver transplantation. METHODS: This retrospective study was reviewed and approved by the institutional review board of the University of Leipzig. Cytomegalovirus (CMV) prophylaxis with valganciclovir hydrochloride for liver transplant recipients was replaced by a preemptive strategy in October 2009. We retrospectively compared liver transplant recipients 2 years before and after October 2009. During the first period, all patients received valganciclovir daily. During the second period all patients included in the analysis were treated following a preemptive strategy. Outcomes included one year survival and therapeutic intervention due to CMV viremia or infection. RESULTS: Between 2007 and 2010 n = 226 patients underwent liver transplantation in our center. n = 55 patients were D(+)/R(-) high risk recipients and were excluded from further analysis. A further 43 patients had to be excluded since CMV prophylaxis/preemptive strategy was not followed although there was no clinical reason for the deviation. Of the remaining 128 patients whose data were analyzed, 60 received prophylaxis and 68 were treated following a preemptive strategy. The difference in overall mortality was not significant, nor was it significant for one-year mortality where it was 10% (95%CI: 8%-28%, P = 0.31) higher for the preemptive group. No significant differences in blood count abnormalities or the incidence of sepsis and infections were observed other than CMV. In total, 19 patients (14.7%) received ganciclovir due to CMV viremia and/or infections. Patients who were treated according to the preemptive algorithm had a significantly higher rate risk of therapeutic intervention with ganciclovir [n = 16 (23.5%) vs n = 3 (4.9%), P = 0.003)]. CONCLUSION: These data suggest that CMV prophylaxis is superior to a preemptive strategy in patients undergoing liver transplantation.
Authors: Raymund R Razonable; Hester van Cruijsen; Robert A Brown; Jennie A Wilson; William S Harmsen; Russell H Wiesner; Thomas F Smith; Carlos V Paya Journal: J Infect Dis Date: 2003-05-09 Impact factor: 5.226
Authors: Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz Journal: Am J Transplant Date: 2004-04 Impact factor: 8.086
Authors: F M Mattes; E G Hainsworth; A F Hassan-Walker; A K Burroughs; P Sweny; P D Griffiths; V C Emery Journal: J Infect Dis Date: 2004-11-29 Impact factor: 5.226
Authors: Carlos V Paya; Jennie A Wilson; Mark J Espy; Irene G Sia; Michael J DeBernardi; Thomas F Smith; Robin Patel; Greg Jenkins; William S Harmsen; David J Vanness; Russell H Wiesner Journal: J Infect Dis Date: 2002-03-19 Impact factor: 5.226
Authors: Cornelius Engelmann; Martina Sterneck; Karl Heinz Weiss; Silke Templin; Steffen Zopf; Gerald Denk; Dennis Eurich; Johann Pratschke; Johannes Weiss; Felix Braun; Martin-Walter Welker; Tim Zimmermann; Petra Knipper; Dirk Nierhoff; Thomas Lorf; Elmar Jäckel; Hans-Michael Hau; Tung Yu Tsui; Aristoteles Perrakis; Hans-Jürgen Schlitt; Kerstin Herzer; Frank Tacke Journal: J Clin Med Date: 2020-07-23 Impact factor: 4.241